Is the keto diet effective for refractory chronic migraine?

Key clinical point: A 3-month ketogenic diet (KD) resulted in a reduction of painful symptoms of drug refractory chronic migraine.

Major finding: KD significantly reduced the number of migraine days/month from a median of 30 days to 7.5 days (P less than .0001), hours of migraine/day from a median of 24 hours to 5.5 hours (P less than .0016), and pain level at maximum value for 83% of participants that improved for 55% of them (P less than .0024). The median number of drugs taken in a month reduced from 30 to 6 doses.

Study details: This open-label, single-arm clinical trial assessed 38 patients with refractory chronic migraine who adopted a KD for 3 months.

Disclosures: No source of funding was declared. The authors declared no conflicts of interest.

Source: Bongiovanni D et al. Neurol Sci. 2021 Feb 1. doi: 10.1007/s10072-021-05078-5.

Key clinical point: A 3-month ketogenic diet (KD) resulted in a reduction of painful symptoms of drug refractory chronic migraine.

Major finding: KD significantly reduced the number of migraine days/month from a median of 30 days to 7.5 days (P less than .0001), hours of migraine/day from a median of 24 hours to 5.5 hours (P less than .0016), and pain level at maximum value for 83% of participants that improved for 55% of them (P less than .0024). The median number of drugs taken in a month reduced from 30 to 6 doses.

Study details: This open-label, single-arm clinical trial assessed 38 patients with refractory chronic migraine who adopted a KD for 3 months.

Disclosures: No source of funding was declared. The authors declared no conflicts of interest.

Source: Bongiovanni D et al. Neurol Sci. 2021 Feb 1. doi: 10.1007/s10072-021-05078-5.

Key clinical point: A 3-month ketogenic diet (KD) resulted in a reduction of painful symptoms of drug refractory chronic migraine.

Major finding: KD significantly reduced the number of migraine days/month from a median of 30 days to 7.5 days (P less than .0001), hours of migraine/day from a median of 24 hours to 5.5 hours (P less than .0016), and pain level at maximum value for 83% of participants that improved for 55% of them (P less than .0024). The median number of drugs taken in a month reduced from 30 to 6 doses.

Study details: This open-label, single-arm clinical trial assessed 38 patients with refractory chronic migraine who adopted a KD for 3 months.

Disclosures: No source of funding was declared. The authors declared no conflicts of interest.

Source: Bongiovanni D et al. Neurol Sci. 2021 Feb 1. doi: 10.1007/s10072-021-05078-5.